347 related articles for article (PubMed ID: 34503294)
1. Organ-Chip Models: Opportunities for Precision Medicine in Pancreatic Cancer.
Haque MR; Rempert TH; Al-Hilal TA; Wang C; Bhushan A; Bishehsari F
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503294
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment.
Haque MR; Wessel CR; Leary DD; Wang C; Bhushan A; Bishehsari F
Microsyst Nanoeng; 2022; 8():36. PubMed ID: 35450328
[TBL] [Abstract][Full Text] [Related]
3. Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening.
Geyer M; Queiroz K
Front Cell Dev Biol; 2021; 9():761807. PubMed ID: 35004672
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring.
Mäkinen L; Vähä-Koskela M; Juusola M; Mustonen H; Wennerberg K; Hagström J; Puolakkainen P; Seppänen H
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158794
[TBL] [Abstract][Full Text] [Related]
5. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.
Suri R; Zimmerman JW; Burkhart RA
Ann Pancreat Cancer; 2020 Dec; 3():. PubMed ID: 33889840
[TBL] [Abstract][Full Text] [Related]
6. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells.
Choi JI; Jang SI; Hong J; Kim CH; Kwon SS; Park JS; Lim JB
Cancer Lett; 2021 Feb; 498():42-53. PubMed ID: 33188841
[TBL] [Abstract][Full Text] [Related]
7. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.
Qu J; Kalyani FS; Liu L; Cheng T; Chen L
Cancer Commun (Lond); 2021 Dec; 41(12):1331-1353. PubMed ID: 34713636
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.
Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X
Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465
[TBL] [Abstract][Full Text] [Related]
9. 3d tissue models as tools for radiotherapy screening for pancreatic cancer.
Wishart G; Gupta P; Schettino G; Nisbet A; Velliou E
Br J Radiol; 2021 Apr; 94(1120):20201397. PubMed ID: 33684308
[TBL] [Abstract][Full Text] [Related]
10. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma.
Bradney MJ; Venis SM; Yang Y; Konieczny SF; Han B
Small; 2020 Mar; 16(10):e1905500. PubMed ID: 31997571
[TBL] [Abstract][Full Text] [Related]
11. Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?
Kokkinos J; Jensen A; Sharbeen G; McCarroll JA; Goldstein D; Haghighi KS; Phillips PA
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34067833
[TBL] [Abstract][Full Text] [Related]
12. Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer.
Brancato V; Comunanza V; Imparato G; Corà D; Urciuolo F; Noghero A; Bussolino F; Netti PA
Acta Biomater; 2017 Feb; 49():152-166. PubMed ID: 27916739
[TBL] [Abstract][Full Text] [Related]
13. Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma.
Swayden M; Soubeyran P; Iovanna J
Front Oncol; 2019; 9():1443. PubMed ID: 32038993
[TBL] [Abstract][Full Text] [Related]
14. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
Sereti E; Papapostolou I; Dimas K
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979869
[TBL] [Abstract][Full Text] [Related]
16. Organ-on-Chip platforms to study tumor evolution and chemosensitivity.
Dsouza VL; Kuthethur R; Kabekkodu SP; Chakrabarty S
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188717. PubMed ID: 35304293
[TBL] [Abstract][Full Text] [Related]
17. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
18. Microengineered Organ-on-a-chip Platforms towards Personalized Medicine.
Kankala RK; Wang SB; Chen AZ
Curr Pharm Des; 2018; 24(45):5354-5366. PubMed ID: 30799783
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.
Frappart PO; Hofmann TG
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987786
[TBL] [Abstract][Full Text] [Related]
20. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.
Nelson SR; Zhang C; Roche S; O'Neill F; Swan N; Luo Y; Larkin A; Crown J; Walsh N
Sci Rep; 2020 Feb; 10(1):2778. PubMed ID: 32066753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
